Management of TIRADS 3 Thyroid Nodules

Definition and Malignancy Risk

The American College of Endocrinology recommends that TIRADS 3 nodules, defined as nodules without suspicious ultrasound characteristics, have a malignancy risk of less than 5% 1

The current recommendations prioritize surveillance for nodules less than 1 cm without suspicious characteristics, even if they are classified as high risk according to certain systems 2
For non-subcapsular TIRADS 3 nodules classified as cT1a cN0, biopsy is not recommended 2

A history of cervical or cephalic irradiation may necessitate further evaluation, even for a TIRADS 3 nodule 1
A family history of thyroid cancer may necessitate further evaluation, even for a TIRADS 3 nodule 1
The presence of suspicious cervical lymph nodes may necessitate further evaluation, even for a TIRADS 3 nodule 1
Subcapsular location of the nodule may necessitate further evaluation, even for a TIRADS 3 nodule 2, 1
Rapidly growing nodules documented during follow-up may necessitate further evaluation, even for a TIRADS 3 nodule 1

A follow-up ultrasound should be performed at 12 months to evaluate nodule stability 1
If the nodule remains stable in size and ultrasound characteristics, surveillance should continue at 12-24 month intervals 1
Thyroid function tests (TSH, T3, T4) should not be relied upon to evaluate malignancy risk, as most thyroid cancers present with normal thyroid function 1

Systematic biopsy of nodules greater than 1 cm without considering TIRADS classification should be avoided, as it leads to overdiagnosis and overtreatment of clinically insignificant cancers 1
Nodules with mild hypoechogenicity should not be confused with those having marked hypoechogenicity, as only the latter is a suspicious criterion justifying reclassification 1
In the presence of multiple nodules, each nodule should be evaluated according to its own TIRADS characteristics rather than biopsying the largest one systematically 1